Ocugen Announces Agreement With Washington University In St. Louis For Commercialization Of Intranasal COVID-19 Vaccine In U.S., Europe And Japan
Ocugen's intranasal candidate is one of the world's most advanced intranasal COVID-19 vaccines
Intranasal vaccine is designed to curb virus transmission and confer protective immunity
MALVERN, Pa., Sept. 28,